Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms.

Salvatore TafutoClaudia Von ArxMonica CapozziFabiana TatangeloManuela MuraRoberta ModicaMaria Luisa BarrettaAntonella Di SarnoMaria Lina TorneselloAnnamaria ColaoAlessandro Ottaiano

Published in: Journal of clinical medicine (2019)

Metronomic TMZ is a suitable treatment for G2 and G3 NENs particularly in PS 2 patients. Prospective and larger trials are needed to confirm these results.

Keyphrases

newly diagnosed
end stage renal disease
ejection fraction
chronic kidney disease
patient reported